Vista previa | Fecha de publicación | Título | Autor(es) | Acceso |
![Tramadol and Cycling Is It the End of a “Painful” Relationship. An Insight From 60,802 Doping-Control Samples From 2012 to 2020.pdf.jpg](/retrieve/12b44654-d1c6-485e-85ca-9094451d80f2/Tramadol%20and%20Cycling%20Is%20It%20the%20End%20of%20a%20%e2%80%9cPainful%e2%80%9d%20Relationship.%20An%20Insight%20From%2060%2c802%20Doping-Control%20Samples%20From%202012%20to%202020.pdf.jpg) | 5-dic-2022 | Tramadol and Cycling: Is It the End of a “Painful” Relationship?. An Insight From 60,802 Doping-Control Samples
From 2012 to 2020 | Zandonai, Thomas; Peiró, Ana; Covelli, Caterina; de la Torre, Xavier; Botré, Francesco | ![](/image/closedAccess.png) |
![Influence of substituents of Perylenebisimides on the surface energy and.pdf.jpg](/retrieve/c3f7ed65-c349-4c11-94c9-39b9050dc3c3/Influence%20of%20substituents%20of%20Perylenebisimides%20on%20the%20surface%20energy%20and.pdf.jpg) | 2022 | Influence of substituents of Perylenebisimides on the surface energy and wettability: A systematic structure–property relationship analysis | Pérez-Ojeda, M.Eugenia; Zink Lorre, Nathalie; Pla, Sara; Sastre-Santos, Ángela; Fernández Lázaro, Fernando; Hirsch, Andreas | ![](/image/closedAccess.png) |
![Oxycodonenaloxone - naloxone versus tapentadol in real-world chronic non-cancer pain management.an observational and pharmacogenetic study.pdf.jpg](/retrieve/49e3f51c-59c2-43d1-9d15-6d348e3d5cf2/Oxycodonenaloxone%20-%20naloxone%20versus%20tapentadol%20in%20real-world%20chronic%20non-cancer%20pain%20management.an%20observational%20and%20pharmacogenetic%20study.pdf.jpg) | jun-2022 | Oxycodone/naloxone versus tapentadol in real-world chronic non-cancer pain management: an observational and pharmacogenetic study | Barrachina, Jordi; Margarit, César; Muriel, Javier; López‑Gil, Santiago; López Gil, Vicente; Vara-González, Amaya; Planelles, Beatriz; Inda, María del Mar; Morales, Domingo; Peiró, Ana | ![](/image/openAccess.png) |
![Long-term deprescription in chronic pain and opioid use disorder patients. Pharmacogenetic and sex differences.pdf.jpg](/retrieve/442d251d-8781-4a09-b495-e3bbda10e4df/Long-term%20deprescription%20in%20chronic%20pain%20and%20opioid%20use%20disorder%20patients.%20Pharmacogenetic%20and%20sex%20differences.pdf.jpg) | 18-nov-2022 | Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences | Muriel, Javier; Escorial, Mónica; Margarit, César; Barrachina, Jordi; Carvajal, Cristian; Morales, Domingo; Peiró, Ana | ![](/image/openAccess.png) |
![CYP2D6 phenotypes and opioid metabolism. the path to personalised analgesia.pdf.jpg](/retrieve/8a3fbbc5-ffc9-46b8-b233-5a18818cb254/CYP2D6%20phenotypes%20and%20opioid%20metabolism.%20the%20path%20to%20personalised%20analgesia.pdf.jpg) | abr-2022 | CYP2D6 phenotypes and opioid metabolism: the path to personalized analgesia | Ballester, Purificación; Muriel, Javier; Peiró, Ana | ![](/image/closedAccess.png) |
![Non-pharmacological therapy in chronic musculoskeletal pain.pdf.jpg](/retrieve/06729c35-a4bc-4468-8fd6-f10e673682c3/Non-pharmacological%20therapy%20in%20chronic%20musculoskeletal%20pain.pdf.jpg) | sep-2022 | Non-pharmacological therapy in chronic musculoskeletal pain | Inda, María del Mar; Margarit, César; Vara, Amaya; Cutillas, Esperanza; Mateu, Marga; Martínez, Evan; Coves, Miriam; Rodríguez, Jorge; Ballester, Purificación; Barrachina, Jordi; Morales, Domingo; Peiró, Ana | ![](/image/closedAccess.png) |
![Benzodiazepines in sport, an underestimated problem. Recommendations for sports medicine physicians’ practice.pdf.jpg](/retrieve/a8eb7ad0-a9db-4620-b281-1033b43f9322/Benzodiazepines%20in%20sport%2c%20an%20underestimated%20problem.%20Recommendations%20for%20sports%20medicine%20physicians%e2%80%99%20practice.pdf.jpg) | 21-dic-2022 | Benzodiazepines in sport, an underestimated problem: Recommendations for sports medicine physicians’ practice | Zandonai, Thomas; Peiró, Ana; FUSINA, FRANCESCA; Lugoboni, Fabio; Zamboni, Lorenzo | ![](/image/openAccess.png) |
![Sex Differences in Oxycodone Naloxone vs. Tapentadol in Chronic Non-Cancer Pain. An Observational Real-World Study.pdf.jpg](/retrieve/a32f4d7a-81ff-4222-8a14-e364812dcd50/Sex%20Differences%20in%20Oxycodone%20Naloxone%20vs.%20Tapentadol%20in%20Chronic%20Non-Cancer%20Pain.%20An%20Observational%20Real-World%20Study.pdf.jpg) | 2-oct-2022 | Sex Differences in Oxycodone/Naloxone vs. Tapentadol in Chronic Non-Cancer Pain: An Observational Real-World Study | Barrachina, Jordi; Margarit, Cesar; Muriel, Javier; López Gil, Vicente; López Gil, Santiago; Ballester, Purificación; Mira-Lorente, Laura; Agulló, Laura; Peiró, Ana | ![](/image/openAccess.png) |
![Therapeutic alliance impact on analgesic outcomes in a real-world clinical setting. An observational study.pdf.jpg](/retrieve/ca542327-61b5-4184-a433-b8037a6f0828/Therapeutic%20alliance%20impact%20on%20analgesic%20outcomes%20in%20a%20real-world%20clinical%20setting.%20An%20observational%20study.pdf.jpg) | 20-mar-2022 | Therapeutic alliance impact on analgesic outcomes in a real-world clinical setting: An observational study | Barrachina, Jordi; Margarit, César; Andreu, Blanca; Zandonai, Thomas; Ballester, Purificación; Muriel, Javier; Cutillas, Esperanza; Peiró, Ana | ![](/image/openAccess.png) |